Search Results

Deals

Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy Regimens

Janssen Biotech, Inc. announced that it has entered into a definitive agreement under which it will acquire BeneVir Biopharm, Inc. (BeneVir), a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies.

May 2, 2018

·

5 min read

File folder with Merger and Acquisition and financial graphs. Business concept

Deals

Janssen Strikes Deal to Acquire BeneVir and its Oncolytic Virus Platform in Deal Worth Up to $1 Billion

Shares of HC2 Holdings, Inc. skyrocketed more than 51 percent in premarket trading today after Janssen Biotech Inc announced it was acquiring Rockville, Maryland-based BeneVir Biopharm, Inc., a subsidiary of HC2 in a deal that could be worth more than $1 billion.

May 2, 2018

·

2 min read

·

Alex Keown

BioCapital

Benevir Biopharm Granted Patent Protecting Lead Oncolytic Immunotherapy Stealth-1H And Other Platform Assets

April 25, 2017

·

3 min read

BioCapital

BeneVir Biopharm, Inc. Announces Investment From HC2’s Subsidiary Pansend, LLC

November 19, 2014

·

1 min read

Drug Development

Benevira Announces Positive Preclinical Data for its Novel COVID-19 Treatment

Benevira today announced positive preclinical safety and efficacy data on β521, a novel SARS-CoV-2 therapy, demonstrating robust tolerability and efficacy against several SARS-CoV-2 variants.

May 24, 2022

·

4 min read

Business

The Week in Review: A Look at Some of the Top Biopharma Stories

Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.

May 3, 2018

·

4 min read

·

Mark Terry

BioCapital

Immunomic CEO to Speak at 2018 BioHealth Capital Region Forum

Panel Will Discuss Strengths in BioHealth Immunotherapies

April 19, 2018

·

3 min read

Deals

Boehringer Ingelheim Expands Oncolytic Virus Program and Buys ViraTherapeutics for $245 Million

Heidelberg, Germany-based Boehringer Ingelheim has exercised its option to buy an EMBL Ventures portfolio company, ViraTherapeutics. This follows a collaboration and option deal inked between the two companies in August 2016.

September 13, 2018

·

3 min read

·

Mark Terry

Biotech Beach

ITI Senior Director of Corporate Development to Participate in an All Women’s Leadership Panel Discussion and Dinner at ISPE’s First Women in Pharma Event

Immunomic Therapeutics Inc. Senior Director of Corporate Development Sia Anagnostou will participate in ISPE’s first Women in Pharma Event in Gaithersburg, MD.

March 22, 2018

·

2 min read

Deals

Flurry of Activity: Top 2018 Biopharma M&A Deals So Far

While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.

May 2, 2018

·

2 min read

·

Mark Terry